Related Experiment Video
Updated: Nov 14, 2025
Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids
Published on: May 4, 2018
Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)
Gabrielle S Dijksteel1,2, Magda M W Ulrich1,2,3, Esther Middelkoop1,2
1Association of Dutch Burn Centres, Beverwijk, Netherlands.
Abstract:
Antimicrobial peptides (AMPs) or host defense peptides protect the host against various pathogens such as yeast, fungi, viruses and bacteria. AMPs also display immunomodulatory properties ranging from the modulation of inflammatory responses to the promotion of wound healing. More interestingly, AMPs cause cell disruption through non-specific interactions with the membrane surface of pathogens. This is most likely responsible for the low or limited emergence of bacterial resistance against many AMPs. Despite the increasing number of antibiotic-resistant bacteria and the potency of novel AMPs to combat such pathogens, only a few AMPs are in clinical use. Therefore, the current review describes (i) the potential of AMPs as alternatives to antibiotics, (ii) the challenges toward clinical implementation of AMPs and (iii) strategies to improve the success rate of AMPs in clinical trials, emphasizing the lessons we could learn from these trials.
Insights
Antimicrobial peptides (AMPs) show potential as antibiotic alternatives due to their membrane-disrupting action, which limits bacterial resistance. This review explores AMPs
Area of Science:
- Microbiology and Immunology
- Drug Discovery and Development
Background:
- Antimicrobial peptides (AMPs), also known as host defense peptides, are crucial components of the innate immune system.
- AMPs exhibit broad-spectrum activity against bacteria, fungi, viruses, and yeast, and possess immunomodulatory functions.
- Their non-specific membrane-disrupting mechanism of action is associated with a low propensity for inducing microbial resistance.
Purpose of the Study:
- To review the potential of AMPs as novel therapeutic agents against the rising threat of antibiotic-resistant bacteria.
- To identify and discuss the key challenges hindering the clinical translation and implementation of AMP-based therapies.
- To propose strategies for enhancing the success rate of AMPs in clinical trials, drawing insights from past experiences.
Main Methods:
- Literature review of existing research on antimicrobial peptides, their mechanisms of action, and clinical trial data.
- Analysis of factors contributing to the limited clinical success of AMPs to date.
- Synthesis of strategies to overcome translational barriers for AMPs.
Main Results:
- AMPs demonstrate significant potential as alternatives to conventional antibiotics due to their unique mechanism of action.
- Several challenges, including toxicity, stability, and formulation, impede the clinical progression of AMPs.
- Lessons learned from clinical trials highlight the need for optimized delivery systems and targeted therapeutic applications.
Conclusions:
- Antimicrobial peptides represent a promising frontier in combating antimicrobial resistance, offering a distinct advantage over traditional antibiotics.
- Addressing the identified challenges through innovative strategies is essential for realizing the full therapeutic potential of AMPs.
- Further research and carefully designed clinical trials are necessary to establish AMPs as a viable clinical treatment option.
